The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

				·
UNIT		AND EXCHAN n, D.C. 20549 RM D	GE COMMISSION	OMB APPROVAL OMB 3235- Number: 0076
	Notice of Exempt	Offering of Secur	rities	Estimated average burden
				hours per 4.00 response:
1. Issuer's Identity				
CIK (Filer ID Num	ber) Previous Names	X None		Entity Type
0001557746			X Corpoi	ation
Name of Issuer			-	d Partnership
Aclaris Therapeutics, Inc.				d Liability Company
Jurisdiction of				l Partnership
Incorporation/Organ	ization			ss Trust
DELAWARE			Other	Specify)
Year of Incorporation	ion/Organization			
Over Five Years Ago				
X Within Last Five Years (Sp	pecity Year) 2012			
Yet to Be Formed				
2. Principal Place of Business	and Contact Information			
Name o	f Issuer			
Aclaris Therapeutics, Inc.				
Street A			Street Address 2	
101 LINDENWOOD DRIVE		Suite 400		
City	State/Province/Country			Number of Issuer
MALVERN	PENNSYLVANIA	19355	484-324-	/933
3. Related Persons				
Last Name	Firs	t Name	Middle	Name
Walker	Neal			
Street Address 1	Street	Address 2		
101 LINDENWOOD DRIVE	Suite 400			
City		vince/Country	ZIP/Pos	talCode
MALVERN	PENNSYLVANIA		19355	
<b>Relationship:</b> X Executive O	Officer X Director Promot	er		
Clarification of Response (if N	Necessary):			
Last Name	Firs	t Name	Middle	Name
Powala	Christopher			
Street Address 1	Street	Address 2		
101 LINDENWOOD DRIVE	Suite 400			
City	State/Prov	vince/Country	ZIP/Pos	talCode

Clarification of Response (if Necessary):

Relationship: X Executive Officer Director Promoter

PENNSYLVANIA

19355

MALVERN

Last Name	First Name	Middle Name
Shanler	Stuart	
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE	Suite 400	
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355
<b>Relationship:</b> X Executive Officer	Director Promoter	
Clarification of Response (if Necess	ary):	
Last Name	First Name	Middle Name
Ali-Jackson	Kamil	
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE		
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355
<b>Relationship:</b> X Executive Officer	Director Promoter	
Clarification of Response (if Necess	ary):	
Last Name	First Name	Middle Name
Ruffo	Frank	
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE	Suite 400	
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355
<b>Relationship:</b> X Executive Officer	Director Promoter	
Clarification of Response (if Necess	ary):	
Last Name	First Name	Middle Name
Tullman	Steven	А.
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE	Suite 400	
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355
<b>Relationship:</b> Executive Officer 2	X Director Promoter	
Clarification of Response (if Necess	ary):	
Last Name	First Name	Middle Name
Bierly	Richard	A.
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE		
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355
<b>Relationship:</b> Executive Officer 2		
Clarification of Response (if Necess	ary):	
Last Name	First Name	Middle Name
Cha	Albert	
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE	Suite 400	
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355

## Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Mehra	Anand	
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE	Suite 400	
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355
<b>Relationship:</b> Executive Offic	er X Director Promoter	
Clarification of Response (if Nec	essary):	

Last Name	First Name	Middle Name
Molineaux	Christopher	
Street Address 1	Street Address 2	
101 LINDENWOOD DRIVE	Suite 400	
City	State/Province/Country	ZIP/PostalCode
MALVERN	PENNSYLVANIA	19355
<b>Relationship:</b> Executive Officer X	Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financia Commercial Bank Insurance Investing Investing Investment Banki Pooled Investment Is the issuer regist an investment con the Investment Co Act of 1940? Yes	ting ng t Fund rered as npany under	Health Care Biotechnology Health Insurance Hospitals & Physicians X Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services
	Financial Services	REITS & Finance	Other Travel
Business Services Energy Coal Mining		Residential Other Real Estate	Other

5. Issuer Size

Oil & Gas

Other Energy

**Electric Utilities** 

Energy Conservation Environmental Services

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000

\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,000,000			
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000			
Over \$100,000,000	Over \$100,000,000			
X Decline to Disclose	Decline to Disclose			
Not Applicable	Not Applicable			
6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)				

Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii) Rule 505 X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)	Investment Co Section 3(c)(2 Section 3(c)(2 Section 3(c)(2 Section 3(c)(2 Section 3(c)(2 Section 3(c)(2)	2) Section 3(c)(10)   3) Section 3(c)(11)   4) Section 3(c)(12)   5) Section 3(c)(13)   6) Section 3(c)(14)
7. Type of Filing		
X New Notice Date of First Sale 2016-06-02 Fir Amendment	st Sale Yet to C	Occur
8. Duration of Offering		
Does the Issuer intend this offering to last more than	one year?	Zes X No
9. Type(s) of Securities Offered (select all that apply)	)	
X Equity Debt Option, Warrant or Other Right to Acquire Anothe Security to be Acquired Upon Exercise of Option, Other Right to Acquire Security	-	Pooled Investment Fund Interests Tenant-in-Common Securities Mineral Property Securities Other (describe)
10. Business Combination Transaction		
Is this offering being made in connection with a busi a merger, acquisition or exchange offer?	iness combinati	on transaction, such as Yes X No
Clarification of Response (if Necessary):		
11. Minimum Investment		
Minimum investment accepted from any outside inv	estor \$0 USD	
12. Sales Compensation		
Recipient William Blair & Company L.L.C.	Recipio 1252	ent CRD Number None
(Associated) Broker or Dealer X None	(Assoc Numbe	iated) Broker or Dealer CRD r
None	None	
Street Address 1		Street Address 2

222 West Adams Street City Chicago

State/Province/Country ILLINOIS

ZIP/Postal Code 60606-5312

X None

State(s) of Solicitation (select all that apply) X All Sta Check "All States" or check individual States	ates Foreign/non-US	
Recipient	Recipient CRD Number None	
Guggenheim Securities, LLC	40638	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number	X None
None	None	
Street Address 1	Street Address 2	
330 Madison Avenue		
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10017
State(s) of Solicitation (select all that apply) Check "All States" or check individual X All Sta States	ates Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$20,000,017 USD or Ind	lefinite	

Total Amount Sold \$20,000,017 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$1,300,001 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

## \$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to

furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Aclaris Therapeutics, Inc.	/s/ Neal Walker	Neal Walker	Chief Executive Officer	2016-06-13

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.